Bio-Techne Corp. (TECH) has been in the news for varied reasons lately. Long term holding potential of the company's stocks is debated while it showcases Next-Generation Solutions for Gene and Cell Therapy at the American Society of Gene & Cell Therapy 2025. Their partnership with Kytopen for advancing Cell Therapy Manufacturing and collaboration with Leica Biosystems for better research workflows underlines their commitment to innovation. However, despite their stock underperforming comparing to competitors on certain days, the market predicts possible spike in BioTechne stocks. Their Q3 2025 earnings highlighted strong organic growth but concerns over NIH’s funding saw the stock slide. Though analysts have lowered their target price, they maintain a buy rating. Excitement surrounds the early access program for Next-Generation Spatial Protein Proximity Detection. With a new share repurchase programs and dividend announcements, the company remains a keen participant in the industry’s future developments.
Bio-Techne Corp TECH News Analytics from Mon, 29 Jul 2024 07:00:00 GMT to Wed, 14 May 2025 20:30:00 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -3
